In a study, Pfizer and BioNTech’s vaccine worked against lab-made coronaviruses similar to variants spreading in the UK and South Africa. Small differences in how the vaccine performed against the mutations, versus the original virus, were “unlikely to lead to a significant reduction” in effectiveness, according to BioNtech. The partners agree they will continue to monitor emerging strains and verify the vaccine’s effectiveness. Meanwhile, they are developing a booster shot that protects against coronavirus variants.

Read Full Story